Humana (HUM) Stock
US health insurer with Medicare Advantage and care services. Here's the price, business snapshot, and what's worth knowing about Humana in August 2026.
Humana Inc (HUM) is a major US health insurance and services company, best known for its large Medicare Advantage business alongside commercial and Medicaid plans. With a market cap around $35.5bn, Humana generates revenues from premiums, care-management services and health-services initiatives that aim to lower costs and improve outcomes. Investors often watch Humana for its exposure to the growing Medicare Advantage market and its push into value-based care, primary-care partnerships and home health services, which can offer structural growth if executed well. Key considerations include reimbursement policy, regulatory oversight, medical-cost trends and membership retention. The stock can be sensitive to election-driven healthcare policy and short-term claims volatility. This summary is educational and not personalised investment advice; returns are not guaranteed and the value of investments can fall as well as rise. Consider your goals, risk tolerance and seek independent advice before investing.
Why It’s Moving
Humana gets a fresh catalyst from a leadership hire, but investors are still pricing in margin risk.
- Humana named physician executive Dr. Shantanu Nundy as its next chief medical officer, a move that signals a sharper focus on care quality and clinical execution as it works through Medicare Advantage pressure.
- The stock has also been reacting to the aftermath of late-July earnings, where Humana beat Q2 expectations but investors stayed cautious because management cut its 2026 outlook and cost trends remain a key concern.
- Broader healthcare sentiment has improved after a run of analyst upgrades and higher price views in early August, suggesting the market is still weighing Humana’s margin recovery potential against ongoing medical-cost risk.
Humana gets a fresh catalyst from a leadership hire, but investors are still pricing in margin risk.
- Humana named physician executive Dr. Shantanu Nundy as its next chief medical officer, a move that signals a sharper focus on care quality and clinical execution as it works through Medicare Advantage pressure.
- The stock has also been reacting to the aftermath of late-July earnings, where Humana beat Q2 expectations but investors stayed cautious because management cut its 2026 outlook and cost trends remain a key concern.
- Broader healthcare sentiment has improved after a run of analyst upgrades and higher price views in early August, suggesting the market is still weighing Humana’s margin recovery potential against ongoing medical-cost risk.
Sixth Month Growth Performance
next-earnings-question
The next Humana earnings date is expected on November 4, 2026, based on its historical reporting pattern. That release should cover fiscal Q3 2026. The company’s investor calendar also shows a related earnings conference call on November 6, 2026.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Humana's stock, which may rise towards its target price of $385.32.
Financial Health
Humana is showing strong revenue and cash flow, indicating solid financial performance and stability.
Dividend
Humana's dividend yield of 0.87% indicates a low return for dividend-seeking investors. If you invested $1000 you would be paid $8.70 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Medicare Advantage Focus
Humana’s scale in Medicare Advantage can be a structural growth engine, though outcomes depend on policy and medical-cost trends.
Care-Delivery Push
Investors may watch its moves into value-based care and home health since these can improve margins over time, but execution risk remains.
Regulatory Sensitivity
Policy and reimbursement changes materially affect profits and membership; consider regulatory risk alongside growth opportunities.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
